Our study proves the feasibility of using perfusion MRIs to identify subpopulations of glioblastoma patients with a higher likelihood of a beneficial effect of standard Stupp treatment (i.e., including TMZ), patients with methylated MGMT, and moderate vascularization in the contrast-enhancing tumor areas. This evidence concerns the gene MGMT and glioblastoma.